Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Sign in

NovaBridge Biosciences

NBP Nasdaq Pharmaceutical Preparations Financials FY2019–FY2025

Add to portfolio Download report

What NovaBridge Biosciences does

NBP Β· Pharmaceutical Preparations

From its latest annual report

No business description yet.

Filing details

Legal name
NovaBridge Biosciences
Fiscal year ends
December 31, 2025
Latest annual report
20-F Β· Apr 7, 2026
Accession Β· CIK
0001778016-26-000002 Β· 0001778016

Earnings calendar Β· NovaBridge Biosciences

Every quarter, companies publish how much they sold and earned. These are the days NovaBridge Biosciences did it, and the next one. Share prices often move a lot on those days.

Next results

April 6, 2027

Tuesday Β· in 162 days

Time
After the market closes
Covers
Period ended Dec 31, 2026
Source
Stoqly estimate

Estimated from the same quarter last year. It will be replaced by the announced date once there is one.

See who else reports that week β†’
Date Results for Time Source
Apr 7, 2026 Q4 '25 After the market closes 20-F β†—
Apr 3, 2025 Q4 '24 After the market closes 20-F β†—
Apr 30, 2024 Period ended Dec 31, 2023 Before the market opens 20-F β†—
May 1, 2023 Period ended Dec 31, 2022 Before the market opens 20-F β†—
Apr 29, 2022 Period ended Dec 31, 2021 After the market closes 20-F β†—
Apr 28, 2021 Q4 '20 Before the market opens 20-F β†—
Apr 29, 2020 Period ended Dec 31, 2019 Before the market opens 20-F β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read NovaBridge Biosciences’s latest annual report (fiscal 2025). Here is what stands out:

2 to watch

NovaBridge Biosciences in 30 seconds

Good So-so Weak

Weak

Does it make a profit?

βˆ’$46.3M

No. It lost money last year.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
β€”
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$4.83 EPS (TTM)

Revenue

Total sales reported in the income statement.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· NovaBridge Biosciences lost $46.3M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was βˆ’$20.6M in fiscal 2025, β€” of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· NovaBridge Biosciences lost $46.3M in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was βˆ’$20.6M in fiscal 2025, β€” of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· In the last 12 months, insiders bought $0.6M and sold $0.2M of shares on the open market.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.6M

1 insider

Sold, 12 months

$0.2M

3 insiders

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
Sep 18, 2026 Phillip Andrew DennisChief Medical Officer Sold 8,209 $0.71 $0.0M Form 4
Sep 9, 2026 Sean Wuxiong CaoChief Bus. Development Officer Sold 107,978 $0.74 $0.1M Form 4
Aug 31, 2026 Cong Claire XuEVP, Clinical Development Sold 3,282 $0.79 $0.0M Form 4
Jul 6, 2026 Cong Claire XuSVP, Clinical Development Sold 4,485 $0.89 $0.0M Form 4
Jun 18, 2026 Phillip Andrew DennisChief Medical Officer Sold 8,494 $0.66 $0.0M Form 4
Jun 1, 2026 Cong Claire XuSVP, Clinical Development Sold 3,494 $3.94 $0.0M Form 4
May 14, 2026 Sean Wuxiong CaoSee Remarks, Director Sold 21,399 $1.99 $0.0M Form 4
Apr 24, 2026 Mark Arnold HaglerSee Remarks Bought 230,000 $2.51 $0.6M Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably NovaBridge Biosciences can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $671M$377M$312M$173M$211M
Debt incl. finance leases β€”$2.7M$4.2Mβ€”β€”
Debt / equity β€”0.0x0.0xβ€”β€”
Interest coverage β€”βˆ’53,078.0xβˆ’706.0xβ€”β€”
Current ratio 7.7x4.8x5.7x20.9x8.1x
Quick ratio 7.6x4.8x5.7x20.9x8.1x
Total assets $879M$591M$369M$213M$261M
Total liabilities $163M$169M$126M$11.5M$29.6M
Shareholders' equity $715M$418M$243M$201M$231M
Net debt (βˆ’ = net cash) β€”βˆ’$374Mβˆ’$308Mβ€”β€”

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ“ βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ“ βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” βœ“ βœ• βœ• βœ“ βœ“ βœ•
Cash from operations exceeds net income βœ“ βœ• βœ“ βœ“ βœ“ βœ• βœ“
Debt fell relative to assets β€” β€” β€” β€” βœ• β€” β€”
Current ratio rose β€” βœ“ βœ• βœ• βœ“ βœ“ βœ•
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ“ βœ•
Gross margin rose β€” β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” βœ“ βœ• βœ• βœ“ β€” β€”
F-score β€” / 35 / 71 / 71 / 74 / 8β€” / 6β€” / 6
Accruals ratio βˆ’33.6%0.9%βˆ’23.0%βˆ’28.7%βˆ’5.0%10.5%βˆ’10.9%
Altman Z'' β€”β€”β€”1.12βˆ’5.632.19βˆ’6.11

All figures

Every number, year by year.

7 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $4.3M $236M $13.8M βˆ’$1.6M $0.6M β€” β€”
Gross profit β€” β€” $6.5M βˆ’$5.5M β€” β€” β€”
Research and development $121M $151M $190M $22.5M $21.4M $21.8M $62.9M
Operating income β€” β€” β€” βˆ’$53.1M βˆ’$72.0M βˆ’$51.4M βˆ’$94.3M
Interest expense $0.4M $0.1M $0.0M $0.0M $0.1M β€” β€”
Pretax income βˆ’$209M $74.0M βˆ’$366M βˆ’$141M βˆ’$82.2M βˆ’$49.7M βˆ’$88.3M
Income tax β€” $1.9M βˆ’$0.5M $0.1M $0.0M $0.0M $0.0M
Net income βˆ’$209M $72.2M βˆ’$366M βˆ’$371M βˆ’$208M βˆ’$22.2M βˆ’$46.3M
Net income to common βˆ’$213M $72.2M βˆ’$366M βˆ’$364M βˆ’$206M β€” β€”
Diluted EPS βˆ’$664.70 $10.58 βˆ’$48.07 βˆ’$45.08 βˆ’$25.07 βˆ’$2.76 βˆ’$4.83
Diluted shares 0.00B 0.01B 0.01B 0.01B 0.01B 0.01B 0.01B
Cash flow
Cash from operations βˆ’$125M $66.4M βˆ’$153M βˆ’$160M βˆ’$184M βˆ’$52.7M βˆ’$20.6M
Capital expenditure $1.8M $1.2M $4.7M $2.1M $0.2M $0.0M $0.0M
Free cash flow βˆ’$126M $65.2M βˆ’$157M βˆ’$162M βˆ’$184M βˆ’$52.7M βˆ’$20.6M
Depreciation and amortization $1.4M $2.0M $2.2M $0.2M $0.5M $0.3M $0.1M
Stock-based compensation $52.7M $75.6M $95.5M $13.1M $10.2M βˆ’$1.9M $6.0M
Balance sheet
Cash and short-term investments $168M $734M $671M $377M $312M $173M $211M
Total debt $7.2M β€” β€” $2.7M $4.2M β€” β€”
Current assets $196M $819M $750M $526M $330M $177M $218M
Current liabilities $84.5M $88.3M $97.9M $110M $58.1M $8.5M $26.9M
Inventory β€” β€” $4.3M $0.0M β€” β€” β€”
Property and equipment, net $4.3M $3.9M $7.2M $8.8M $1.8M $0.2M $0.1M
Goodwill $23.4M $24.9M $25.5M $23.6M β€” β€” β€”
Intangible assets $21.4M $18.5M $18.8M $17.2M $16.6M β€” β€”
Total assets $250M $971M $879M $591M $369M $213M $261M
Total liabilities $96.0M $108M $163M $169M $126M $11.5M $29.6M
Shareholders' equity βˆ’$292M $862M $715M $418M $243M $201M $231M
Margins
Gross margin β€” β€” 47.3% 354.6% β€” β€” β€”
Operating margin β€” β€” β€” 3,422.2% βˆ’11,395.1% β€” β€”
EBITDA margin β€” β€” β€” 3,409.3% βˆ’11,316.0% β€” β€”
Net margin βˆ’4,840.1% 30.5% βˆ’2,648.7% 23,923.5% βˆ’32,868.5% β€” β€”
FCF margin βˆ’2,934.2% 27.6% βˆ’1,139.5% 10,443.8% βˆ’29,107.9% β€” β€”
Returns
Return on capital β€” β€” β€” βˆ’96.4% β€” β€” β€”
Return on capital employed β€” β€” β€” βˆ’11.0% βˆ’23.2% βˆ’25.2% βˆ’40.4%
Return on equity β€” 25.3% βˆ’46.4% βˆ’65.5% βˆ’62.9% βˆ’10.0% βˆ’21.4%
Return on assets βˆ’83.6% 11.8% βˆ’39.6% βˆ’50.5% βˆ’43.3% βˆ’7.6% βˆ’19.6%
Return on tangible equity β€” 8.8% βˆ’54.5% βˆ’96.4% βˆ’91.4% βˆ’11.1% βˆ’20.0%
Growth
Revenue growth β€” 5,386.7% βˆ’94.2% βˆ’111.2% β€” β€” β€”
Net income growth β€” β€” βˆ’607.0% β€” β€” β€” β€”
EPS growth β€” β€” βˆ’554.3% β€” β€” β€” β€”
FCF growth β€” β€” βˆ’341.3% β€” β€” β€” β€”
Share count change β€” 2,030.3% 11.1% 8.6% 0.9% βˆ’2.5% 18.0%
Financial health
Debt / equity β€” β€” β€” 0.0x 0.0x β€” β€”
Interest coverage β€” β€” β€” βˆ’53,078.0x βˆ’706.0x β€” β€”
Current ratio 2.3x 9.3x 7.7x 4.8x 5.7x 20.9x 8.1x
Quick ratio 2.3x 9.3x 7.6x 4.8x 5.7x 20.9x 8.1x
Capital allocation
Capex / revenue 40.8% 0.5% 34.0% βˆ’134.8% 25.9% β€” β€”
Stock comp / revenue 1,223.0% 32.0% 691.4% βˆ’847.8% 1,620.1% β€” β€”
Quality scores
Piotroski F-score β€” 5.0 1.0 1.0 4.0 β€” β€”
Altman Z'' β€” β€” β€” 1.1 βˆ’5.6 2.2 βˆ’6.1
Accruals ratio βˆ’33.6% 0.9% βˆ’23.0% βˆ’28.7% βˆ’5.0% 10.5% βˆ’10.9%

Source: SEC EDGAR XBRL filings (CIK 0001778016). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Per-share figures are per US-listed share (1 ADS = 23 ordinary shares). For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open